Clinical Trials Logo
  1. Home
  2. BPH
  3. NCT00527488

Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.

BPH Clinical Trial

Official title:
A Single-centre, Open-label, Randomised Explorative Pharmacokinetic/Pharmacodynamic Study of the Gonadotropin-releasing Hormone Receptor Antagonist Degarelix (FE 200486) in Patients With Benign Prostatic Hyperplasia.

Clinical Trial Summary

This exploratory study will be conducted open label in a single investigational clinical unit. Altogether 52 patients with benign prostate hyperplasia (BPH) will be randomly assigned to receive 4 different treatments with degarelix.

Clinical Trial Description

The present study aims at exploring the potential of the currently available formulation of degarelix to treat BPH with only a short transient lowering of the serum testosterone concentration to or below the castration level defined as 0.5 ng/mL. Two doses and two dosing regimens (32 and 64 mg administered either as a single administration or as two administrations separated by 14 days) will be evaluated for 42 days. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00527488
Study type Interventional
Source Ferring Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date October 2007
Completion date May 2009
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02974751 - Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
Terminated NCT04398966 - Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia N/A
Completed NCT04029012 - Penthrox in Rezūm BPH Phase 4
Recruiting NCT03912558 - Pilot Study to Assess the Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in BPH Patients. N/A
Recruiting NCT06323109 - US Imaging for the Assessment of LUTS
Completed NCT05628025 - Simulation-Based Enucleation Training: Initial Experience Using 3D-printed Organ Phantoms
Completed NCT00407329 - Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia N/A
Completed NCT00256399 - Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED) N/A
Terminated NCT03994263 - A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI N/A
Completed NCT03772808 - Effects of LycoComfort™ Supplementation on Symptoms Associated With Lower Urinary Tract Symptoms (LUTS) N/A
Completed NCT05818670 - Comparison Between Tamsulosin and Tadalafil in Management of Benign Prostatic Hyperplasia Long Term Study Phase 4
Withdrawn NCT02961114 - Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Phase 1/Phase 2
Active, not recruiting NCT04198103 - Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia N/A
Completed NCT00696761 - The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients Phase 4
Completed NCT00199550 - Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP) Phase 4
Completed NCT02702947 - Efficacy of Prunus Domestica Extract in BPH Phase 4
Completed NCT00154843 - A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation Phase 2
Completed NCT00037141 - Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) Phase 1/Phase 2
Recruiting NCT05620784 - Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP Phase 3
Not yet recruiting NCT05719220 - Effect of Group Preoperative Pelvic Floor Training for HoLEP